Previous studies demonstrated that analogs of benztropine [3␣-(diphenyl-methoxy)tropane (BZT)] bind to the dopamine (DA) transporter with high affinity, inhibit DA uptake, but do not maintain rates of responding in self-administration procedures comparable with those maintained by cocaine. Some BZT analogs have an onset of action that is slower than that for cocaine that may contribute to this decreased effectiveness. In addition, some BZT analogs have affinity for muscarinic-M1 receptors that may interfere with reinforcing effects. The present study assessed effects of BZT analogs in place-conditioning procedures designed to accommodate variations in onset of effect. Benztropine [BZT; 3␣-(diphenylmethoxy)tropane] is the parent compound in a class of dopamine (DA) transport inhibitors with structural similarity to cocaine (i.e., a tropane ring), as well as to the 1,4-dialyky(en)ylpiperazines (i.e., a diphenyl-ether moiety), exemplified by GBR 12909. A series of BZT analogs showed enhanced affinities for binding to the DA transporter relative to BZT and cocaine . Despite this increased affinity, the behavioral effects of these compounds were generally different from those of cocaine and other DA uptake inhibitors. For example, 4-chloro-3␣-(diphenylmethoxy)tropane (4-Cl-BZT) has a 30 nM affinity for the DA transporter, which is comparable with the high-affinity binding of cocaine. However, 4-Cl-BZT has reduced effectiveness as a stimulant of locomotor activity compared with cocaine and does not produce cocaine-like discriminative stimulus effects Tolliver et al., 1999). Furthermore, this compound does not maintain rates of responding as high as those maintained by cocaine in a self-administration procedure (Woolverton et al., 2000) or break points as high as those for cocaine under a progressive ratio schedule (Woolverton et al., 2001). The differences between the BZT analogs compared with cocaine may appear at odds with the DA transporter hypothesis of the behavioral effects of cocaine, which suggests that compounds that bind to the DA transporter and inhibit DA uptake will have behavioral effects like those of cocaine (Kuhar et al., 1991).Some of the BZT analogs have a time course that is different from that of cocaine. For example, Tolliver et al. (1999) and Tanda et al. (2003) showed that increases in extracellular DA produced by cocaine occurred sooner after injection than those produced by the 4-Cl analog of BZT. Those results with 4-Cl-BZT are similar to results for BZT reported previously (Church et al., 1987). A pharmacokinetic comparison of cocaine and a series of BZT analogs indicated that all of these Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.